Motexafin lutetium hydrate (Synonyms: PCI-0123; PCI 0123; PCI0123; Lu texaphyrin; LuTex; Lutetium texaphyrin; Lutrin; Optrin; Brand name: Antrin. Pubchem: CID 9919942) |
Catalog No.GB62173 |
Motexafin lutetium is a texaphyrin, marketed as Antrin by Pharmacyclics Inc.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 156436-90-7
Sample solution is provided at 25 µL, 10mM.
Motexafin lutetium is a texaphyrin, marketed as Antrin by Pharmacyclics Inc. Motexafin lutetium is structurally a pentadentate aromatic metallotexaphyrin with photosensitizing properties. Motexafin lutetium preferentially accumulates in tumor cells due to their increased rates of metabolism and absorbs light, forming an extended high energy conformational state that produces high quantum yields of singlet oxygen, resulting in local cytotoxic effects. M otexafin lutetium is a photosensitiser for use in photodynamic therapy to treat skin conditions and superficial cancers. It has also been tested for use in photoangioplasty (photodynamic treatment of diseased arteries). It is photoactivated by 732 nm light which allows greater depth of penetration.
Review for Motexafin lutetium hydrate
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)Review for Motexafin lutetium hydrate
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *